Lynthera Corporation

Medtech · Private

Drug-delivery contact lens platform using boundary charge modifiers to extend olopatadine release in silicone hydrogel lenses

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · lynthera.com

Sector: Medtech
Total capital: $9.1M

Federal grants: $9.1M; 18 awards · 2016–2025; Rank in peer group#102 of 538
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Aug 2025Federal grantHealth and Human S · Phase II · Drug delivery platform for ocular allergy therapy$900K
Aug 2024Federal grantHealth and Human S · Phase II · Drug delivery platform for ocular allergy therapy$900K
May 2024Federal grantHealth and Human S · Phase II · Sustained delivery technology for Cyclosporine A in the treatment of autoimmune response$795K
Apr 2024Federal grantHealth and Human S · Phase I · I-Corps for Novel Formulation Technology for Sustained Release Naloxone$55K
Sep 2023Federal grantHealth and Human S · Phase I · Novel formulation technology for the sustained release naloxone to improve outcomes in the management of opioid overdose$320K
Sep 2023Federal grantHealth and Human S · Phase I · Novel formulation technology for the sustained release naloxone to improve outcomes in the management of opioid overdose$320K
Jun 2023Federal grantHealth and Human S · Phase II · Sustained delivery technology for Cyclosporine A in the treatment of autoimmune response$795K

Show 11 earlier federal awards

Aug 2022Federal grantHealth and Human S · Phase I · Drug delivery platform for ocular allergy therapy$300K
Jul 2022Federal grantHealth and Human S · Phase I · Drug delivery platform for ocular allergy therapy$300K
Apr 2021Federal grantHealth and Human S · Phase I · Sustained delivery technology for Cyclosporine A in the treatment of autoimmune response$300K
Jul 2020Federal grantHealth and Human S · Phase II · Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection$169K
May 2019Federal grantHealth and Human S · Phase II · Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection$754K
Jun 2018Federal grantHealth and Human S · Phase II · Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection$1.7M
May 2018Federal grantHealth and Human S · Phase II · Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection$755K
Sep 2016Federal grantHealth and Human S · Phase I · Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection$31K
Sep 2016Federal grantHealth and Human S · Phase I · Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection$256K
Jun 2016Federal grantNSF · Phase I · SBIR Phase I: Contact lens with innovative nanoparticles for multi-week, controlled delivery of glaucoma drugs$225K
Apr 2016Federal grantHealth and Human S · Phase I · Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 538 peers

Line = median

Medtech · Device

Federal grants#102 · top 19%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Arthur YangResearcherDirectorLinked by $5.1M in grants as PI
Caesar LuoDirectorNamed in SEC Form D filings
Jeff YangExecutive Officer, DirectorNamed in SEC Form D filings
Solomon LuoDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

JT-MESH DIAGNOSTICS LLCSimilar federal contract value in Medtech · null in contracts
BLUMIO, INC.Similar federal contract value in Medtech · null in contracts
MPROBE, INC.Similar federal contract value in Medtech · null in contracts
CATS TONOMETER, LLCSimilar federal contract value in Medtech · null in contracts
GODX INCSimilar federal contract value in Medtech · null in contracts
DEEPCONVO INC.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.